Meeting
2015 ASCO Annual Meeting
Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
Authors
Beatrice Bachmeier
Institute of laboratory medicine, Ludwig-Maximilians-University, Munich, Germany
Beatrice Bachmeier , Jeff Sperinde , Jodi Marie Weidler , Yolanda Lie , Ahmed Chenna , John Winslow , Jutta Engel , Gabriele Schubert-Fritschle , Christian Sommerhoff , Christos J. Petropoulos , Michael Patrick Bates , Weidong Huang , Andreas Nerlich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 593)
DOI
10.1200/jco.2015.33.15_suppl.593
Abstract #
593
Poster Bd #
82
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2017 ASCO Annual Meeting
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
First Author: Maria Alsina
Poster
2014 ASCO Annual Meeting
Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.
First Author: Paolo Nuciforo
Poster
2013 ASCO Annual Meeting
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment.
First Author: Yeon Hee Park